Develops cancer drugs.
Jun 2026Revenue $117M/yrExpenses $603M/yr
No trendCash runway ≈ 1.5 years from Jun 2026
Figures by year
When will Arcus Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $117M and expenses $603M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $247M | $633M | −$386M |
| Dec 2024 | $258M | $588M | −$330M |
| Dec 2023 | $117M | $457M | −$340M |
| Dec 2022 | $112M | $392M | −$280M |
| Dec 2021 | $383M | $329M | $54.0M |
| Dec 2020 | $78.0M | $202M | −$124M |
| Dec 2019 | $15.0M | $104M | −$88.7M |
| Dec 2018 | $8.35M | $63.2M | −$54.9M |
| Dec 2017 | $1.41M | $54.9M | −$53.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.